-
1001
-
1002
-
1003
Editorial: Global advances in the diagnosis, management, and treatment of low back pain
Published 2025-02-01Get full text
Article -
1004
Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study
Published 2018-01-01Get full text
Article -
1005
Obesity and Cytokines in Childhood-Onset Systemic Lupus Erythematosus
Published 2014-01-01“…We screened consecutive cSLE patients followed up in the Pediatric Rheumatology Outpatient Clinic of the State University of Campinas. …”
Get full text
Article -
1006
-
1007
Update on the Medical Management of Gastrointestinal Behçet’s Disease
Published 2017-01-01Get full text
Article -
1008
-
1009
IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma
Published 2021-01-01Get full text
Article -
1010
-
1011
-
1012
-
1013
Brief intervention to reduce fatigue impact in patients with inflammatory arthritis: design and outcomes of a single-arm feasibility study
Published 2022-07-01“…We developed a manualised, one-to-one, cognitive–behavioural intervention, delivered by rheumatology health professionals (RHPs). The Fatigue - Reducing its Effects through individualised support Episodes in Inflammatory Arthritis (FREE-IA) study tested the feasibility of RHP training, intervention delivery and outcome collection ahead of a potential trial of clinical and cost-effectiveness.Methods In this single-arm feasibility study, eligible patients were ≥18 years, had a clinician-confirmed diagnosis of an inflammatory arthritis and scored ≥6/10 on the Bristol Rheumatoid Arthritis Fatigue (BRAF) Numerical Rating Scale (NRS) Fatigue Effect. …”
Get full text
Article -
1014
Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis
Published 2019-01-01Get full text
Article -
1015
Insulin Resistance in Osteoarthritis: Similar Mechanisms to Type 2 Diabetes Mellitus
Published 2020-01-01Get full text
Article -
1016
-
1017
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
Published 2025-01-01“…Disease response assessed using non-responder imputation plateaued at LTE week 12 before slowly declining over time, with overall American College of Rheumatology (ACR)20/50/70 response rates of 26.9%/20.2%/14.7% at week 396.Conclusion Filgotinib was well tolerated in patients with RA for up to 8 years. …”
Get full text
Article -
1018
-
1019
Toll-Like Receptor Signaling Pathways—Therapeutic Opportunities
Published 2010-01-01Get full text
Article -
1020
Early Disseminated Lyme Disease with Carditis Complicated by Posttreatment Lyme Disease Syndrome
Published 2017-01-01Get full text
Article